Brief: Senti Bio Announces Strategic Steps To Prioritize Investment In Lead Clinical Program

Senti Biosciences Holdings

05/01/2024 22:19

Jan 5 (Reuters) - Senti Biosciences Inc  SNTI.O :
    * SENTI BIO ANNOUNCES STRATEGIC STEPS TO PRIORITIZE
INVESTMENT IN
LEAD CLINICAL PROGRAM
    * SENTI BIOSCIENCES INC - ANTICIPATED COST SAVINGS, WHICH
INCLUDES
AN APPROXIMATELY 37% REDUCTION IN WORKFORCE, EXPECTED TO EXTEND
CASH RUNWAY INTO 1Q 2025
    * SENTI BIOSCIENCES - ANTICIPATED COST SAVINGS, WHICH
INCLUDES AN
APPROXIMATELY 37% REDUCTION IN WORKFORCE, EXPECTED TO EXTEND
CASH RUNWAY INTO 1Q 2025
    * SENTI BIOSCIENCES INC - STRATEGIC RESOURCE ALLOCATION TO
FOCUS
INVESTMENT ON CLINICAL DEVELOPMENT OF SENTI-202 AND SENTI-301A
PARTNERSHIP IN CHINA
    * SENTI BIOSCIENCES INC - INTERIM DATA FROM PHASE 1 CLINICAL
TRIAL
OF SENTI-202 EXPECTED IN 2H 2024
    * SENTI BIOSCIENCES INC - REDUCE CURRENT HEADCOUNT BY
APPROXIMATELY 37 PERCENT
    * SENTI BIOSCIENCES INC- EXPECTS TO INCUR ONE-TIME COSTS OF
APPROXIMATELY $1 MILLION
    * SENTI BIOSCIENCES INC - REDUCE CURRENT HEADCOUNT BY
APPROXIMATELY 37 PERCENT; ANTICIPATED TO BE COMPLETED IN Q1 OF
2024

Source text for Eikon:  ID:nGNX94T4F5 
Further company coverage:  SNTI.O